Physician profile
Hans E Bone
NPI 1265734214
$3,027.24
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $39.35 · 2023: $2,266 · 2024: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,332 · Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,331.78 |
| Food and Beverage | $1,233.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,070.19 | 2023 | Synchromedii |
| Averitas Pharma INC. | $160.46 | 2023-2024 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.73 | 2021-2023 | Relistor |
| Pfizer INC. | $107.70 | 2021-2024 | |
| Collegium Pharmaceutical, INC. | $82.93 | 2021-2023 | Belbuca |
| Vertex Pharmaceuticals Incorporated | $79.55 | 2024 | |
| Biodelivery Sciences International, INC. | $76.42 | 2021 | |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Abbvie INC. | $67.07 | 2021-2024 | |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $39.35 | 2022 | |
| Baudax Bio INC. | $18.69 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.20 | 2024 | Austedo Xr |
| Merck Sharp & Dohme LLC | $15.41 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hans Bone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.